A Phase II, Multi-Centre, Randomized, Double-Blind Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA or Fulvestrant Plus Placebo in Postmenopausal Women With Bone Only or Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2014
At a glance
- Drugs Vandetanib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Bone metastases
- Focus Biomarker; Therapeutic Use
- Acronyms ZAMBONEY
- 10 Jun 2017 Biomarkers information updated
- 04 Jun 2013 Primary endpoint 'Biochemical-response-rate' has not been met.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History